Asunto(s)
Linfoma de Células B Grandes Difuso/radioterapia , Recurrencia Local de Neoplasia/patología , Neoplasias Cutáneas/radioterapia , Anciano de 80 o más Años , Resultado Fatal , Fluorodesoxiglucosa F18 , Humanos , Linfoma de Células B Grandes Difuso/patología , Masculino , Tomografía de Emisión de Positrones , Radiofármacos , Neoplasias Cutáneas/patologíaAsunto(s)
Enfermedad de Hodgkin/patología , Linfoma de Células B Grandes Difuso/patología , Micosis Fungoide/patología , Neoplasias Primarias Múltiples/patología , Neoplasias Cutáneas/patología , Anciano , Antígenos CD20/metabolismo , Resultado Fatal , Enfermedad de Hodgkin/inmunología , Enfermedad de Hodgkin/metabolismo , Humanos , Inmunohistoquímica , Hibridación in Situ , Antígeno Ki-1/metabolismo , Linfoma de Células B Grandes Difuso/inmunología , Linfoma de Células B Grandes Difuso/metabolismo , Masculino , Micosis Fungoide/inmunología , Micosis Fungoide/metabolismo , Neoplasias Primarias Múltiples/inmunología , Neoplasias Primarias Múltiples/metabolismo , Neoplasias Cutáneas/inmunología , Neoplasias Cutáneas/metabolismoAsunto(s)
Fallo Hepático/etiología , Micosis Fungoide/complicaciones , Neoplasias Cutáneas/complicaciones , Dermis/patología , Progresión de la Enfermedad , Resultado Fatal , Hepatitis/etiología , Humanos , Inmunohistoquímica , Hígado/diagnóstico por imagen , Ganglios Linfáticos/diagnóstico por imagen , Masculino , Persona de Mediana Edad , Micosis Fungoide/tratamiento farmacológico , Micosis Fungoide/patología , Terapia PUVA , Tomografía de Emisión de Positrones , Neoplasias Cutáneas/tratamiento farmacológico , Neoplasias Cutáneas/patologíaRESUMEN
The remission period of psoriasis vulgaris following narrowband ultraviolet B (NB-UVB) light therapy with topical vitamin D(3) application was evaluated retrospectively to investigate the therapeutic efficacy. Fifty-two patients (60 cases) were treated with a 5-day/week protocol of NB-UVB light irradiation plus topical vitamin D ointment application for 1 month and followed up for at least 12 months. We considered re-exacerbation as the time when the patients needed treatment other than topical therapy. The remission period was defined as the duration from the end of treatment until re-exacerbation. Twenty-seven cases (56%) of psoriasis showed a remission period longer than 12 months. The patients with a past history of systemic therapy or phototherapy had a significantly shorter remission period than those without such a history. No statistically significant differences were observed in sex, age, period before treatment, Psoriasis Area and Severity Index score and total irradiation dose. A previous history of systemic therapy or phototherapy may mean that the disease is severe and sufficiently active to form multiple new lesions requiring these treatments. Our results suggest that the 5-day/week NB-UVB light protocol for 4 weeks is an effective and safe treatment for psoriasis vulgaris and can induce long-term remission.
Asunto(s)
Psoriasis/radioterapia , Terapia Ultravioleta , Administración Tópica , Adolescente , Adulto , Anciano , Anciano de 80 o más Años , Calcitriol/administración & dosificación , Calcitriol/análogos & derivados , Terapia Combinada , Fármacos Dermatológicos/administración & dosificación , Femenino , Humanos , Masculino , Persona de Mediana Edad , Psoriasis/tratamiento farmacológico , Inducción de Remisión , Estudios Retrospectivos , Factores de Tiempo , Resultado del Tratamiento , Adulto JovenRESUMEN
Early inflammatory changes in psoriatic plaques were investigated immunohistochemically by studying the normal-appearing skin adjacent to the plaques (perilesional skin), lesional skin, and distant uninvolved skin from psoriasis patients. Perilesional epidermis contained numerous CD1a-positive Langerhans cells, some of which expressed HLA-DR, CD83, CD80, and CD86, at the same time expressing Langerin. There were also numerous CD83-positive, CD11c-positive, Langerin-negative dendritic cells (DCs) in the epidermal-dermal junction of perilesional skin. CD3-positive T lymphocytes were sparse in the perilesional skin. Perilesional epidermis expressed keratin K6 and K16, inflammatory keratins, and C/EBPbeta, a transcription factor related to inflammatory cytokines. Our results demonstrated the abundant distribution of activated DCs in the perilesional skin of psoriatic plaques, where early inflammatory changes occur in the epidermal keratinocytes, which suggests their involvement in the provocation of epidermal inflammation in the perilesional epidermis and further pathogenic roles in the formation of psoriatic plaques.